| Active substance | dostarlimab |
| Holder | GlaxoSmithKline Pharmaceuticals S.A./N.V. |
| Status | Running |
| Indication | in combination with carboplatin-paclitaxel as first-line treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy |
| Public documents | Approbation |
| Approbtion amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 31/01/2024 |